Evidence map›Paper›PMID 41836517›Full record

ReviewBMJ oncology2026

Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection.

Beatriz Jimenez-Munarriz, Berenice Urtecho, Mary R Rabey, Natasha B Leighl

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Beatriz Jimenez-MunarrizMedical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-6059-2154
Berenice UrtechoMedical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Mary R RabeyMedical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Natasha B LeighlMedical Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-3249-4602

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumour DNA (ctDNA) offers a minimally invasive approach for early detection of cancer, monitoring molecular residual disease, assessing molecular response and identifying treatment resistance in advanced stages. Additionally, ctDNA enhances clinical decision-making by enabling real-time tumour assessment. This review highlights the growing role of liquid biopsy as a predictive and prognostic tool in non-small cell lung cancer management.

Indexed as

Lung cancer (non-small cell)Tumour biomarkers

Identifiers

PMID41836517
PMCPMC12983876

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.